Moderna, Inc. Hits New 52-Week High of $73.28, Signaling Recovery

Moderna, Inc., a mid-cap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 73.28 on June 30, 2026. This achievement marks a notable rebound from its 52-week low of USD 22.29, showcasing the stock's recent upward momentum. Despite this positive price movement, the company's one-year performance reflects a decline of 52.87%, contrasting sharply with the S&P 500's gain of 20.86% over the same period. Moderna's market capitalization stands at approximately USD 19,573 million, indicating its substantial presence in the industry. Financial metrics reveal that Moderna is currently loss-making, with a negative return on equity of -32.62% and a debt-to-equity ratio of -0.60. The stock does not offer a dividend yield, and its price-to-book ratio is 2.26. As the company continues to navigate the competitive landscape of pharmaceuticals and biotechnology, this recent high may signal a pivotal moment in its market trajectory.